Novo Nordisk A/S (FRA:NOVA)
Germany · Delayed Price · Currency is EUR | Market Cap | 164.25B -14.0% |
| Revenue (ttm) | 44.65B +5.7% |
| Net Income | 15.14B +9.1% |
| EPS | 3.38 +9.2% |
| Shares Out | n/a |
| PE Ratio | 10.92 |
| Forward PE | 12.35 |
| Dividend | 1.11 (3.01%) |
| Ex-Dividend Date | Aug 17, 2026 |
| Volume | 490 |
| Open | 36.42 |
| Previous Close | 36.32 |
| Day's Range | 36.42 - 37.34 |
| 52-Week Range | 30.45 - 54.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Novo Nordisk A/S maintains a leading position in the high-growth obesity and diabetes treatment markets. Pfizer offers a highly diversified product portfolio and significant free cash flow generation.
Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A
(RTTNews) - Novo Nordisk (NVO, NOVOB.CO, NOV.DE) has received European Commission marketing authorization for FREHEMGO (denecimig), a next-generation therapy for the routine prophylaxis of bleeding ep...
Novo's haemophilia drug gets EU approval
Novo Nordisk said on Friday the European Commission has granted approval for its treatment to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A, a rare blo...
Novo Nordisk submits etavopivat NDA to FDA, etavopivat MAA to EMA
Novo Nordisk (NVO) announced the submissions of a new drug application, or NDA, to the FDA and a marketing authorization application, or MAA, to the European Medicines Agency, or EMA,…
Novo Nordisk says Wegovy pill to cost up to $395 per month
The Danish drugmaker has announced the recommended pricing for its Wegovy tablet that is expected to go on sale in Australia by the end of the year.
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the cou...
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
DJ Khaled has been losing weight with Wegovy® (semaglutide) injection for a year and is eager to keep going and put in the work Khaled will share his experience and invite fans to follow his progress ...
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Novo Nordisk Commits $200 Million To Expand Diabetes Prevention And Care In Developing
(RTTNews) - Novo Nordisk (NVO) has pledged $200 million over the next 10 years to support the World Diabetes Foundation (WDF) in expanding diabetes prevention and care programs across low-and middle-i...
Novo commits $200 million to the World Diabetes Foundation
Novo Nordisk said on Wednesday it will commit $200 million to the World Diabetes Foundation over 10 years starting 2027, supporting the organization's work to strengthen diabetes prevention and care i...
FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – w...
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
The US Food and Drug Administration (FDA) told makers of popular weight-loss GLP-1 drugs that they must add warning labels about a rare eye condition that can cause sudden blindness. Manufacturers of ...
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
These stocks have been going in different directions over the past year, but that trend may not necessarily continue.
The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.
The updated labeling covers Mounjaro, Zepbound, Ozempic and Wegovy.
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of the...
FDA orders blindness risk warning on weight loss drugs
Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administrati...
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
U.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.
Lilly's Foundayo pill cuts sleep apnea severity by up to 44% in late-stage trial, with an FDA filing planned by year-end
Eli Lilly's daily obesity pill Foundayo cut breathing interruptions during sleep by up to 44% in a year-long Phase 3 program. Lilly plans to seek U.S. approval for obstructive sleep apnea by the end o...
US FDA orders new eye risk warnings for Ozempic, Zepbound
The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and diabetes...
Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?
GLP-1 medications and dietary supplements could play complementary roles in managing obesity and supporting longer-term health, Novonesis CEO Ester Baiget told CNBC on Monday. "We have scientific evi...
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.
Novo entered the GLP-1 space ahead of Lilly, but has since lost its lead. Both of these players launched new GLP-1 drugs, the first in pill form, this year.
Novartis drops heart drug after it failed to prevent heart attacks
Novartis is ending development of pelacarsen in heart disease. In a study of more than 8,300 patients the drug cut Lp(a) levels by 78% but did not reduce heart attacks or strokes.
Wegovy's making WAVES as weight loss drug demand surges
Novo Nordisk President and CEO Mike Doustdar discusses the success of the Wegovy weight loss pill. He explains how high efficacy and convenience are driving earnings.